Supplemental Table II: Baseline Pulmonary Function Test, Imaging and Echocardiographic Characteristics of the Study Cohort

Characteristics	All PAH (N=576)	Subgroup[†] (N=282)
Pulmonary function test, % predicted	**(N=466)**	**(N=233)**
• Forced expiratory volume (n)	76 ± 19 (457)	80±18 (230)
• Forced vital capacity (n)	78 ± 18 (455)	84±17 (230)
• FEV1/FVC (n)	89 ± 13 (311)	89±13 (149)
• Total lung capacity (n)	88 ± 20 (419)	94±17 (206)
• Diffusion lung capacity of carbon monoxide (n)	55 ± 23 (409)	63±22 (197)
CT chest[‡]	**(N=306)**	**(N=132)**
• Normal, n (%)	213 (70)	111 (84)
• Interstitial lung disease, n (%)	59 (19)	7 (5)
• Thromboembolism, n (%)	5 (2)	3 (2)
• Other, n (%)	29 (9)	11 (9)
Ventilation/Perfusion scan	**(N=419)**	**(N=221)**

• Normal, n (%)	321 (77)	164 (74)
• Mottled, n (%)	85 (20)	50 (23)
• Intermediate-high probability, n (%)	13 (3)	7 (3)
Echocardiography	**(N=510)**	**(N=248)**
• Ejection Fraction	60±10 (284)	60±9 (127)
• Left atrial enlargement, n (%)	112 (22)	36 (15)
• Right atrial enlargement, n (%)	437 (86)	222 (91)
• Right ventricular hypertrophy, n (%)	232 (45)	118 (48)
• Tricuspid regurgitation, m^2/sec (n)	4.1±0.9 (246)	4.2±0.8 (122)

PAH = pulmonary arterial hypertension, FEV1 = forced expiratory volume in one second, and FVC = forced vital capacity

† = subgroup includes patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension

‡ = high resolution computerized tomographic scan of the chest